AI Summary & Key Takeaways
AI InsightThere was a significant difference between the presence of LAP and ILD and EULAR primary Sjogren's syndrome disease activity ındex (ESSDAI) activity scores of two groups.Conclusion: In our study, an increased risk was observed for both hematological [SIR27.27 (95% CI 5.6-79.7)] and solid malignancies [SIR 7.75 (95% CI 3.9-13.9)] in Sjogren's Syndrom.
📌 3 Key Takeaways
Abstract
Objective: In this study, we aimed to present malignancy data in patients who were followed up in our outpatient clinic with a diagnosis of primary Sjogren’s syndrome (pSS).Methods: Data of 151 patients diagnosed with pSS between 2004-2019 were retrospectively reviewed and clinical, demographic characteristics of 14 patients diagnosed with malignancy were examined. Standardized incidence ratios (SIRs) were calculated.Results: All 14 patients with malignancy were female, their mean age was 55.9±12 years, and the disease duration was 10.5±5.3 years. Malignancy was detected in 9% of the patients who were followed up with the diagnosis of pSS. One patient was diagnosed with cervix cancer (CA), four patients with breast CA, three patients with thyroid papillary CA, one patient with MALT (mucosa-associated lymphoid tissue) lymphoma, one patient with diffuse large B-cell lymphoma (DLBCL), one patient with mycosis fungoides, one patient with vulvar epithelial carcinoma, and two patients with lung CA. Patients with malignancy and those without were compared in terms of clinical and laboratory findings. There was a significant difference between the presence of LAP and ILD and EULAR primary Sjogren's syndrome disease activity ındex (ESSDAI) activity scores of two groups.Conclusion: In our study, an increased risk was observed for both hematological [SIR27.27 (95% CI 5.6-79.7)] and solid malignancies [SIR 7.75 (95% CI 3.9-13.9)] in Sjogren's Syndrom.
Özet
Amaç: Bu çalışmada, polikliniğimizde primer Sjögren sendromu (pSS) tanısı ile takip edilen hastalarda malignite verilerini sunmayı amaçladık.Yöntem: 2004-2019 yılları arasında pSS tanısı alan 151 hastanın verileri retrospektif olarak incelendi ve malignite tanısı alan 14 hastanın klinik, demografik özellikleri değerlendirildi. Standardize insidans oranları (SIR'ler) hesaplandı.Bulgular: Malignite saptanan 14 hastanın tamamı kadın, yaş ortalaması 55.9±12 yıl ve hastalık süresi 10.5±5.3 yıl idi. pSS tanısı ile takip edilen hastaların %9'unda malignite saptandı. Bir hastaya serviks kanseri, dört hastaya meme kanseri, üç hastaya tiroid papiller karsinom, bir hastaya MALT (mukoza ile ilişkili lenfoid doku) lenfoma, bir hastaya diffüz büyük B hücreli lenfoma (DBBHL), bir hastaya mikozis fungoides, bir hastaya vulvar epitelyal karsinom ve iki hastaya akciğer kanseri tanısı konulmuştu. Malignitesi olan ve olmayan hastalar klinik ve laboratuvar bulguları açısından karşılaştırıldı. İki grupta lenfadenopati ve interstisyel akciğer hastalığı varlığı ile EULAR primer Sjögren sendromu hastalık aktivite indeksi (ESSDAI) aktivite skorları arasında anlamlı fark vardı.Sonuç: Çalışmamızda Sjögren Sendromunda hem hematolojik [SIR27.27 (%95 CI 5.6-79.7)] hem de solid maligniteler [SIR 7.75 (%95 CI 3.9-13.9)] için risk artışı gözlendi.